canakinumab
novartis
['mds', 'canakinumab']
congress | #ash22
guillermo garcia-manero discussed a phase ii trial of canakinumab in pts with lower-risk #mds. canakinumab was found to decrease the frequencies of hscs and mpps. canakinumab was safe and there were no severe aes.
#mdssm #medicalcongress 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm